A supplement found in every gym bag in America might also help the body fight tumors, according to new lab research out of UCLA.
Quick Take
- UCLA researchers found creatine boosts dendritic cells and T cells, two immune cell types that attack tumors, in mouse studies.
- Earlier work from the same lab showed creatine also fuels killer T cells as they battle cancer.
- A separate 2026 study found creatine raised tumor metastasis in mice and made platelets more active in healthy human volunteers.
- Experts note most lab findings in mice never turn into real cancer treatments for people.
How Creatine Powers Immune Cells Against Tumors
Researchers at the University of California, Los Angeles gave mice daily creatine, either by injection or through their diet. The mice had a type of melanoma, a serious skin cancer. Creatine activated dendritic cells, the immune system’s scouts that flag tumors for destruction, and tumor growth slowed down in the treated mice. The study appeared in the journal iScience.
The same research team also tested human cells in lab dishes. Creatine boosted activation in human monocyte-derived dendritic cells too, the UCLA newsroom reported, suggesting the effect isn’t limited to mice. That matters because dendritic cells essentially train the rest of the immune system to recognize and attack cancer, making them a prime target for new therapies.
The Same Molecule That Fuels Muscles Fuels T Cells
This isn’t the first time UCLA scientists have linked creatine to cancer immunity. Earlier research from the same lab showed creatine acts like a battery for CD8 T cells, the immune system’s frontline killers. Supplementing creatine in mouse tumor models boosted T cell power and worked even better when paired with existing immunotherapy drugs.
A Competing Finding Raises Metastasis Questions
Not every study tells the same story. A 2026 paper found that creatine supplementation actually promoted tumor metastasis in mice through a pathway involving platelets, the blood cells that help form clots. The mechanism involved an enzyme called megakaryocyte creatine kinase B, paired with a signaling protein named STAT5B.
That same study included eleven healthy human volunteers who took 20 grams of creatine daily for two weeks. Their platelets became more reactive, though none developed cancer or metastasis themselves, since that part of the research was done only in mice. One industry outlet pointed out the study’s headline claims went further than what the actual data showed, a reminder that eye-catching titles don’t always match the fine print.
Why Early Lab Results Rarely Settle the Science
Mouse studies are a starting point, not a finish line. Reviews of drug development show roughly nine out of ten candidates that look promising in early trials fail once tested in people, often because animal models don’t fully capture human biology. That base rate doesn’t mean creatine will fail, but it explains why a cancer surgeon or oncologist won’t yet call it a treatment.
Clinical trials in actual cancer patients have so far been underwhelming on other fronts too. One trial gave 263 patients with incurable illness a high dose of creatine followed by a maintenance dose, and most measured benefits didn’t show up. The honest takeaway is simple common sense: let real-world patient trials, not a single mouse study or a viral headline, decide what goes in your medicine cabinet. Anyone on cancer treatment should talk with their own doctor before adding any supplement, creatine included.
Sources:
newsroom.ucla.edu, pmc.ncbi.nlm.nih.gov, liliyanglab.com, enfaf.com, x.com
